Cargando…

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).

Cisplatin-based combination chemotherapy is frequently used to treat patients with carcinoma of unknown primary site (CUPS). Response rates in the literature range from 12% to 26% and median survival from 5 to 7 months. The goal of this study was to evaluate the combination of carboplatin and prolon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warner, E., Goel, R., Chang, J., Chow, W., Verma, S., Dancey, J., Franssen, E., Dulude, H., Girouard, M., Correia, J., Gallant, G.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150411/ https://www.ncbi.nlm.nih.gov/pubmed/9649162

Ejemplares similares

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
por: Piga, A, et al.
Publicado: (2004)

A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
por: McClay, E. F., et al.
Publicado: (1993)

Carboplatin/etoposide: Neutropenia and thrombocytopenia: case report
Publicado: (2021)

Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
por: Folprecht, Gunnar, et al.
Publicado: (2020)

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma
por: Franceschi, E, et al.
Publicado: (2004)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
por: Comella, P., et al.
Publicado: (1996)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.
por: English, M. W., et al.
Publicado: (1996)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)

Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro
por: Narayana, Revu V. L., et al.
Publicado: (2021)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer
por: Ghielmini, M, et al.
Publicado: (1999)

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
por: Horwich, A, et al.
Publicado: (2000)

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study
por: CAUBET, MATTHIEU, et al.
Publicado: (2015)

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
por: Kamitani, Rei, et al.
Publicado: (2022)

Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma
por: Aoyama, Takashi, et al.
Publicado: (2018)

Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’
por: Conway, Alicia-Marie, et al.
Publicado: (2018)

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
por: Yonemori, K, et al.
Publicado: (2009)

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
por: Matsui, K., et al.
Publicado: (1998)

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma
por: HATAYAMA, YOSHIOMI, et al.
Publicado: (2013)

Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2016)

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
por: Teicher, Beverly A., et al.
Publicado: (2017)

Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?
por: Asom, Anase S., et al.
Publicado: (2022)

Erratum in: Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro
Publicado: (2022)

Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report
por: Yamamoto, Yoshihiro, et al.
Publicado: (2022)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
por: Konings, Inge R. H. M., et al.
Publicado: (2008)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

Phase I Study and Clinical Pharmacological Evaluation of Daily Oral Etoposide Combined with Carboplatin in Patients with Lung Cancer
por: Ohune, Terumasa, et al.
Publicado: (1995)

Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023)

Germline genetics of cancer of unknown primary (CUP) and its specific subtypes
por: Hemminki, Kari, et al.
Publicado: (2016)

Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
por: Es, Hamidreza Aboulkheyr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cimff5eeoihltm2r5ebrg2e45r